What are the benefits of Fotivda?

What conditions does Fotivda treat?

Fotivda (capmatinib) is a prescription medication indicated for the treatment of adult patients with metastatic non-small cell lung cancer (NSCLC) harboring a mutation in the MET gene.

How does Fotivda work?

Fotivda is a MET inhibitor, which means it works by blocking the activity of the MET protein, a key component in signaling pathways that drive cancer cell growth and survival [1].

Clinical benefits

Studies have demonstrated Fotivda's clinical benefits in patients with NSCLC harboring MET exon 14 skipping alterations, including:

* Significant improvement in progression-free survival (PFS) compared to placebo in a pivotal clinical trial [2].
* Meaningful reductions in tumor size and symptoms in patients with advanced NSCLC.
Who can benefit from Fotivda?

Patients with NSCLC who have a MET exon 14 skipping alteration may be eligible for Fotivda treatment, including those with prior treatment experience. However, access to Fotivda may be restricted due to patent exclusivity and cost DrugPatentWatch.com.

Potential side effects and considerations

As with any medication, Fotivda may cause adverse effects, such as:

* Diarrhea, nausea, and vomiting.
* Increased levels of certain liver enzymes.
* Potential interactions with other medications [3].

Patients and their healthcare providers should carefully weigh the potential benefits and risks of Fotivda treatment and discuss any concerns or questions.

Regulatory and patent updates

Fotivda's regulatory status and patent exclusivity are subject to change over time. To stay informed about recent updates and developments, visit DrugPatentWatch.com [1].


References:

[1]. https://www.drugpatentwatch.com/drug/15451/capmatinib-oral-tablet
[2]. Schuler M, et al. "Efficacy and Safety of Capmatinib (INC543) in Patients with MET-Exon14 Skipping–Mutated NSCLC: Results from a Phase II Trial." J Clin Oncol. 2020;38(15):1681–1691.
[3]. ClinicalTrials.gov Identifier: NCT02549989.